Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment
Advances in Pharmacology · 2023 · 31-54
DOI: 10.1016/bs.apha.2023.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacology, 2023. Verfasst von Garry M Walsh. Beteiligte Einrichtung: Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. Electronic address: g.m.walsh@abdn.ac.uk. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. Electronic address: g.m.walsh@abdn.ac.uk.
Zitieren
APA
Walsh, G. M. (2023). Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Advances in Pharmacology, 31-54. https://doi.org/10.1016/bs.apha.2023.04.003
Vancouver
Walsh GM. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Advances in Pharmacology. 2023:31-54. doi:10.1016/bs.apha.2023.04.003
BibTeX
@article{Walsh2023,
author = {Walsh, Garry M},
title = {Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment},
journal = {Advances in Pharmacology},
year = {2023},
pages = {31--54},
doi = {10.1016/bs.apha.2023.04.003}
}
EUVIMED